When the autumn booster programme begins next month, many people are likely to receive Moderna’s new bivalent vaccine, designed to protect against the original Covid strain and the more transmissible Omicron variant. As Covid continues to evolve, so will vaccination strategies. Here we look at some of the developments in the pipeline.
In the past two years we have watched natural selection in action, with successive strains of Covid emerging, each more transmissible and better able to evade previous immunity than the last. To combat this, vaccine manufacturers have updated vaccines to more closely match strains in circulation, with Moderna’s bivalent vaccine the first to be approved that targets two strains simultaneously (the original variant and Omicron). A Pfizer/BioNTech bivalent vaccine is also under review. These updated vaccines are likely to be more effective (we have yet to get conclusive efficacy data), so they will be valuable for ensuring that people at greatest risk of severe illness remain protected against hospitalisation and death. But there are diminishing returns on deploying these vaccines in the wider population because they do not prevent infection and only prevent symptomatic disease for a few months.
The first generation of Covid vaccines all work by boosting circulating antibodies. But they do little to stimulate antibodies in the tissues that line the nose and airways, and this so-called mucosal immunity is the body’s first line of defence against respiratory infection. This is considered a major weakness of current Covid vaccines and could explain why current vaccines protect against illness and death but not against infection. Scientists hope nasal vaccines, similar to those used for seasonal flu, could overcome this shortcoming and help weaken the chain of transmission and reduce the continued impact of Covid. There are at least 12 nasal vaccines in clinical development, with four in phase 3 trials, and many view an effective nasal vaccine as the next major prize for vaccine research.
One company, Vaxart, has developed a tablet that showed promising results in a small trial last month. The aspirin-sized pill uses an adenovirus, similar to the delivery system used by the Oxford/AstraZeneca vaccine, to deliver instructions for making the Covid spike protein to cells in the gut. This stimulates the release of antibodies in the nose and mouth. In the trial, nearly half of volunteers showed higher levels of antibodies in nasal and saliva samples than people whose antibodies were the result of a previous Covid infection. The enhanced antibody levels lasted for six months, according to the trial results. A phase 2 trial with 900 participants is under way and expected to report next year.
Last month there was a call from the White House to develop vaccines designed to protect against future Covid-19 variants, and even unknown coronaviruses that could emerge in the future. At the more modest end of the spectrum – although still a major advance on current vaccines – scientists are working on vaccines with broad immunity against current and future Covid-19 strains. These would be designed to sidestep the continual game of catchup with newly emerging variants.
The Walter Reed Army Institute of Research in the US has the only pan-coronavirus vaccine candidate of this type in clinical trials. Other teams are exploring the even more ambitious goal of developing a vaccine that would work for the entire coronavirus family, including the viruses that cause Mers, Sars and seasonal colds. However, achieving this is some way off and is perhaps best viewed as pandemic preparedness research rather than something likely to yield a new Covid vaccine that could be widely deployed in the next year.
Daegu Gyeongbuk Institute of Science & Technology (DGIST, President Yang Kook) Professor Hongsoo Choi’s team of the Department of Robotics and Mechatronics Engineering collaborated with Professor Sung-Won Kim’s team at Seoul St. Mary’s Hospital, [...]
Tiny nets woven from DNA strands can ensnare the spike protein of the virus that causes COVID-19, lighting up the virus for a fast-yet-sensitive diagnostic test—and also impeding the virus from infecting cells, opening [...]
Roughly two decades ago, a strategy called optogenetics emerged to control brain activity with lasers. It uses viruses to insert genes into cells that make them sensitive to light. Optogenetics has revolutionized neuroscience by giving researchers [...]
Shigella bacteria, which causes Shigellosis, is the primary cause of bacterial diarrhea and diarrheal death among juveniles under five years of age. Because of the antibiotic resistance of Shigella strains, no commercial vaccines are available to date. [...]
Scientists have built microscopic robots equipped with electronic “brains” that are capable of walking autonomously. A team from Cornell University in the US developed the solar-powered bots as part of research into a new generation of [...]
Blood samples from patients with long COVID who are still suffering from fatigue and shortness of breath after a year show signs of autoimmune disease, according to a study published today (Thursday) [...]
High-grade serous ovarian cancer (HGSOC) is among the deadliest human cancers and its prognosis remains extremely poor. An article published in Advanced Science explored the self-therapeutic properties of gold nanoparticles to identify a molecular axis that [...]
Antimicrobial peptides (AMPs) have a broad spectrum of antimicrobial activity and lyse microbial cells by interaction with biomembranes, offering great potential in designing new therapeutics. The antimicrobial resistance (AMR) caused due to overuse of [...]
Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a [...]
Hyperspectral microscopy is an advanced visualization technique that combines hyperspectral imaging with state-of-the-art optics and computer software to enable rapid identification of nanomaterials. Since hyperspectral datacubes are large, their acquisition is complicated and time-consuming. [...]
Malignant brain tumors are cancerous growth in the brain with the possibility of spreading to other parts of the central nervous system (CNS). Brain tumors are highly invasive and have devastating consequences, poor prognosis, [...]
An ultrathin invention could make future computing, sensing and encryption technologies remarkably smaller and more powerful by helping scientists control a strange but useful phenomenon of quantum mechanics, according to new research recently published [...]
Methacrylate-based materials are often used in bone cement and dental resins. However, they have high failure rates as they undergo damage within ten years, impacting the quality of patient’s life and increasing healthcare costs. [...]
Early diagnosis of an infectious viral disease can help the patients and health care professionals monitor the outbreaks accurately and provide treatment at the early stage of a disease, avoiding any detrimental consequences. The [...]
Researchers at Duke University have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell. Loaded with light scattering dyes called Raman reporters commonly used [...]
A household microwave oven modified by a Cornell Engineering professor is helping to cook up the next generation of cellphones, computers and other electronics after the invention was shown to overcome a major challenge [...]